Table 3.

Comparison of clinical response between ANA titer ≤ 1:80 and ≥ 1:160

	ANA titer
	Before IFX			After IFX
EULAR	≤ 1:80	≥ 1:160	P valuea	≤ 1:80	≥ 1:160	P valuea
response	(n = 79)	(n = 27)		(n = 56)	(n = 38)
Good	66%	26%	< 0.001	77%	11%	< 0.001
(remission)	(16%)	(7%)	< 0.001	(59%)	(3%)	< 0.001
Moderate	9%	33%	< 0.001	7%	29%	< 0.001
No	25%	41%	< 0.001	16%	60%	< 0.001

ANA, antinuclear antibodies; IFX, infliximab; ^aAnalyzed with a χ² test.